AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

Retail stocks were in focus on Monday as broker commentary moved share prices, while takeover speculation was pushing the ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...